Connect with us

Health

Psychedelics as potential mental health treatment are explored by Trump administration

Published

on

Psychedelics as potential mental health treatment are explored by Trump administration

NEWYou can now listen to Fox News articles!

The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared.

“The Department shares the goal of ensuring that all Americans — especially our nation’s veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression,” a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. 

“Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges.”

FDA APPROVES FIRST AI TOOL TO PREDICT BREAST CANCER RISK

Advertisement

In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin (“magic mushrooms”) to treat mental health disorders.

MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings.

Psychedelics research has gained support from the Trump administration for treating PTSD and mental health conditions. (iStock)

Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has “a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision.”

Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico.

Advertisement

‘Showing promise’

Psychedelic medicines are “showing real promise,” according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London.

Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves.

COMMON SUPPLEMENTS AND MEDICATIONS COULD CAUSE LIVER DAMAGE, STUDIES SHOW

“Take psilocybin, for example — it’s demonstrating remarkable results for severe depression that hasn’t responded to other medications,” he told Fox News Digital. “MDMA is showing similar breakthroughs for PTSD treatment.”

Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added.

Advertisement

In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin to treat mental health disorders. (iStock)

Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. 

“Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it’s crucial that we complete this research properly,” he said. “The goal is to bring safe, proven psychedelic therapies to the patients who need them most.”

Potential for veterans

At President Trump’s May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that “we’re opening up the possibility of psychedelic treatment.”

Retired Army Sergeant Jonathan Lubecki recently told Fox News’ Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. 

Advertisement

The VA is now opening up to the possibility of psychedelic treatment to promote the health of veterans. (iStock)

“[I] took my first dose of MDMA. I’ve only taken it three times as part of the clinical trial, haven’t taken it since, and haven’t found the need to take it since, because I haven’t had PTSD,” he said. 

Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. 

FALLUJAH VET TURNS MEDAL OF HEROISM INTO A HEALING MISSION FOR FELLOW WARRIORS WITH SERVICE DOGS PROGRAM

“Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions,” he said.

Advertisement

The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate.

“The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions,” said Kasperowicz.

Psilocybin is a Schedule I drug under the Controlled Substances Act, but psilocybin-assisted therapy is legal in Oregon, Colorado and New Mexico. (iStock)

An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is “unlike classical psychedelics.”

Advertisement

The study noted, “MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The researchers concluded that MDMA showed “enhanced levels of trust, empathy, self-compassion and a ‘window of tolerance’” that traditional psychotherapy lacks. 

The VA currently has 11 psychedelic clinical trials in various phases.  (iStock)

Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that “the time is now to address the mental health crisis.”

Advertisement

He said it is “gratifying” that administration officials value the potential benefits of looking into alternative mental health treatments. 

“The time is now to address the mental health crisis.”

Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD).

“In Cybin’s completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003,” said Drysdale.

Risks and cautions

Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News’ senior medical analyst, previously interviewed two of the country’s top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone.

Advertisement

“There is a huge downside in terms of unregulated recreational uses.”

“They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses,” Siegel told Fox News Digital at the time.

Experts emphasize the importance of administering psychedelics in a safe setting when treating mental health conditions. (iStock)

“Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts,” Siegel added.

Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it’s important to administer psychedelics in a safe setting when treating mental health conditions.

Advertisement

For more Health articles, visit www.foxnews.com/health

“Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia,” Moss previously told Fox News Digital. “Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials.”

To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. 

Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed reporting.

Advertisement

Health

Scientists pinpoint why COVID vaccine may trigger heart inflammation in certain people

Published

on

Scientists pinpoint why COVID vaccine may trigger heart inflammation in certain people

NEWYou can now listen to Fox News articles!

POST-DOSE PATTERN — New research reveals why the COVID vaccine can trigger heart issues, especially in one group

PREVENTION PAYOFF — Simple lifestyle changes could slash heart attack risk for millions

A new study has identified why mRNA COVID-19 vaccines could trigger heart issues, especially in one demographic. (iStock)

SMOKE SCREEN — A major cannabis study finds little proof for popular medical claims and flags big dangers

Advertisement

HIDDEN LINK — A common dental health issue may hint at a dangerous cardiovascular condition

SIGN UP FOR OUR HEALTH NEWSLETTER

SCREENING DEBATE A new study questions whether annual mammograms are necessary for most women

SUPER SPREAD — An “aggressive” new flu variant sweeps the globe as doctors warn of severe symptoms

The flu season has intensified as the new H3N2 variant causes severe illness worldwide. (iStock)

Advertisement

DANGEROUS DEFICIT — A nutrient deficiency has been linked to heart disease risk for millions

LIKE WHAT YOU’RE READING? CLICK HERE FOR MORE HEALTH NEWS

CORONARY CHRISTMAS — Holiday heart attacks spike as doctors share hidden triggers and prevention tips

Continue Reading

Health

Aging-related joint disorder increasingly affects people under 40, study finds

Published

on

Aging-related joint disorder increasingly affects people under 40, study finds

NEWYou can now listen to Fox News articles!

Cases of gout are rising in younger individuals, according to a global study.

The condition, which is a type of inflammatory arthritis, steadily increased in people aged 15 to 39 between 1990 and 2021, researchers in China announced.

Although rates vary widely between countries, the total number of young people with the condition is expected to continue rising through 2035.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT

Advertisement

The study, published in the journal Joint Bone Spine, investigated 2021 data from the Global Burden of Disease (GBD), spanning 204 countries within the 30-year timeframe.

The data measured gout prevalence, incidence and years lived with disability, tracking global trends over time. The results showed a global increase across all three outcomes.

Gout is expected to continue rising in young people through 2035. (iStock)

Prevalence and disability years increased by 66%, and incidence rose by 62%. In 2021, 15- to 39-year-olds accounted for nearly 14% of new gout cases globally, the study found.

Men from 35 to 39 years old and people in high-income regions had the highest burden, but high-income North America topped the list for highest rates.

Advertisement

‘SKINNY FAT’ WARNING ISSUED AS STUDY FINDS HIDDEN OBESITY BEHIND NORMAL BMI

Men were also found to have lived more years with gout due to high BMI, while women tended to have the condition as a link to kidney dysfunction, the study noted.

The total number of cases is expected to increase globally due to population growth, but the study projected that rates per population would decrease.

The researchers noted that data quality, especially in low-income settings, could have posed a limitation to the broad GBD data.

What is gout?

Gout is a common form of arthritis involving sudden and severe attacks of pain, swelling, redness and tenderness in the joints, according to Mayo Clinic. It most often occurs in the big toe.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The condition occurs when urate crystals accumulate in the joint. These form when there are high levels of uric acid in the blood, which the body produces when it breaks down a natural substance called purines.

A gout flare-up can happen at any time, often at night, causing the affected joint to feel hot, swollen, tender and sensitive to the touch.

Urate crystals, described as sharp and needle-like, build up in the joint, causing intense pain and swelling. (iStock)

Purines can also be found in certain foods, like red meat or organ meats like liver and some seafood, including anchovies, sardines, mussels, scallops, trout and tuna, according to the Mayo Clinic. Alcoholic drinks, especially beer, and drinks sweetened with fruit sugar can also lead to higher uric acid levels.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Uric acid will typically dissolve in the blood and pass through the kidneys into urine, but when the body produces too much or too little uric acid, it can cause a build-up of urate crystals. These are described by the Mayo Clinic as sharp and needle-like, causing pain, inflammation and swelling in the joint or surrounding tissue.

Risk factors for gout include a diet rich in high-purine foods and being overweight, which causes the body to produce more uric acid and the kidneys to have trouble eliminating it.

Experts urge patients to seek medical attention for gout flare-ups. (iStock)

Certain conditions like untreated high blood pressure, diabetes, obesity, metabolic syndrome and heart and kidney diseases can increase the risk of gout, as well as certain medications.

Advertisement

A family history of gout can also increase risk. Men are more likely to develop the condition, as women tend to have lower uric acid levels, although symptoms generally develop after menopause.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Untreated gout can cause worsening pain and joint damage, experts caution. It may also lead to more severe conditions, such as recurrent gout, advanced gout and kidney stones.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The Mayo Clinic advises patients to seek immediate medical care if a fever occurs or if a joint becomes hot and inflamed, which is a sign of infection. Certain anti-inflammatory medications can help treat gout flares and complications.

Advertisement

Fox News Digital reached out to the researchers for comment.

Continue Reading

Health

New study questions whether annual mammograms are necessary for most women

Published

on

New study questions whether annual mammograms are necessary for most women

NEWYou can now listen to Fox News articles!

A new study suggests that annual mammograms may not be the only effective approach for preventing breast cancer.

The research, published in the Journal of the American Medical Association (JAMA), tested a risk-based breast cancer screening approach against standard annual mammography.

The WISDOM randomized clinical trial, led by study authors from universities and healthcare systems across the U.S., considered more than 28,000 women aged 40 to 74 years old, splitting them into a risk-based screening group and an annual mammography group.

ERIN ANDREWS HAD ‘NO SYMPTOMS’ BEFORE CANCER DIAGNOSIS, PUSHES FOR EARLY SCREENINGS

Advertisement

Researchers calculated each woman’s individual risk based on genetics (sequencing of nine breast cancer genes) and other health factors. 

A new study suggests that annual mammograms may not be the only effective approach for preventing breast cancer. (iStock)

Those who were at the highest risk were advised to alternate between a mammogram and an MRI scan every six months. Patients with elevated risk were told to get an annual mammography and counseling.

Average-risk women were guided to get mammograms every two years, while low-risk individuals were advised to have no screening until they became higher risk or reached age 50.

HIDDEN TYPE OF BREAST CANCER COULD BE EXPOSED BY NEW BREAKTHROUGH TECH

Advertisement

The researchers found that risk-based screening did not lead to more advanced cancer diagnoses (stage 2B or higher) compared with annual screening, indicating that it is just as safe as traditional methods. The risk-based approach, however, did not reduce the number of biopsies overall, as researchers had hoped.

Among the risk-based group of women, those with higher risk had more screening, biopsies and detected cancers. Women at lower risk had fewer procedures.

The research, published in the Journal of the American Medical Association (JAMA), tested a risk-based breast cancer screening approach against standard annual mammography. (iStock)

“[The] findings suggest that risk-based breast cancer screening is a safe alternative to annual screening for women aged 40 to 74 years,” the researchers noted in the research summary. “Screening intensity matched individual risk, potentially reducing unnecessary imaging.”

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

Fox News medical contributor Dr. Nicole Saphier, associate professor of radiology at Memorial Sloan Kettering Cancer Center in New Jersey, commented that while these findings are important, the study “completely sidelines” what screenings are designed to do — detect cancer early.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“If you don’t measure stage 0, stage 1 or stage 2A cancers, you can’t tell whether personalized screening delays diagnosis in a way that matters for survival and treatment intensity,” Saphier, who was not involved in the study, told Fox News Digital in an interview.

Those who were at the highest risk were advised to alternate between a mammogram and an MRI scan every six months. (iStock)

More than 60% of breast cancers in the U.S. are diagnosed at stage 1 or 2A, where cure rates exceed 90%, the doctor noted.

Advertisement

The trial doesn’t “fully evaluate” whether risk-based screening changes detection at the earliest and most treatable stages, where screening “delivers its greatest benefit,” according to Saphier.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Mammography is not without risk — radiation exposure, false positives, anxiety and potential over-diagnosis are real and should be acknowledged,” she said. “But it remains the most effective, evidence-based tool for detecting breast cancer early, when treatment is most successful.”

The expert added that labeling women under 50 as “low risk” is “outdated,” as breast cancer diagnoses are on the rise in younger females.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

“Until long-term mortality data support alternative approaches, annual screening beginning at 40 for average risk women should continue,” Saphier added. “Women should be assessed for breast cancer risk by 25 years old to determine if screening should begin earlier.”

Continue Reading
Advertisement

Trending